Literature DB >> 14755810

Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR-DIRECT trial).

Julinda Mehilli1, Adnan Kastrati, Josef Dirschinger, Lena Etzel, Hildegard Bollwein, Jürgen Pache, Helmut Schühlen, Nicolas Von Beckerath, Melchior Seyfarth, Claus Schmitt, Albert Schömig.   

Abstract

The objective of this randomized study was to assess whether direct stenting leads to less restenosis than does conventional stenting (CS) with predilation in clinical practice. We included 910 patients who were randomly assigned to undergo either direct stenting (DS; n = 456) or CS (n = 454). No significant difference was observed in the incidence of angiographic restenosis (primary endpoint): 23.6% for DS and 21.0% for CS (P = 0.41; relative risk = 1.1; 95% CI = 0.8-1.5). The incidence of target vessel revascularization was 17.3% among DS and 14.8% among CS patients (P = 0.29; relative risk = 1.2; 95% CI = 0.8-1.6). The combined incidence of death or myocardial infarction at one year was 9.0% in the DS group and 7.0% in the CS group (P = 0.28). In conclusion, direct stenting is not associated with any reduction of thrombotic and restenotic complications as compared to the conventional stenting. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14755810     DOI: 10.1002/ccd.10706

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  2 in total

1.  A comparative study of restenosis rates in bare metal and drug-eluting stents.

Authors:  Shilpi Mohan; Anil Dhall
Journal:  Int J Angiol       Date:  2010

2.  In-hospital and mid-term adverse clinical outcomes of a direct stenting strategy versus stenting after pre-dilatation for the treatment of coronary artery lesions.

Authors:  M Alidoosti; M Salarifar; S E Kassaian; A M Zeinali; M S Fathollahi; M R Dehkordi
Journal:  Cardiovasc J Afr       Date:  2008 Nov-Dec       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.